img

Global Specific Antiviral Drugs for COVID-19 Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Specific Antiviral Drugs for COVID-19 Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Due to the COVID-19 pandemic, the global Specific Antiviral Drugs for COVID-19 market size was US$ million in 2023 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the forecast period 2023-2033. Fully considering the economic change by this health crisis, Tablet accounting for % of the Specific Antiviral Drugs for COVID-19 global market in 2023, is projected to value US$ million by 2033, growing at a revised % CAGR from 2023 to 2033. While Mild Symptom Patient segment is altered to an % CAGR throughout this forecast period.
The global key companies of Specific Antiviral Drugs for COVID-19 include Sanofi, Novartis, Shanghai Zhongxisanwei, Teva, Zydus Cadila, Mylan, Apotex, Advanz Pharma and Sun Pharma, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
The United States Specific Antiviral Drugs for COVID-19 market size was US$ million in 2023, while China size was US$ million. The proportion of the United States was % in 2023, while China percentage was %, and it is predicted that China share will reach % in 2033, trailing a CAGR of % through the analysis period. As for the Europe Specific Antiviral Drugs for COVID-19 landscape, Germany is projected to reach US$ million by 2033. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Specific Antiviral Drugs for COVID-19 market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Specific Antiviral Drugs for COVID-19 market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Specific Antiviral Drugs for COVID-19 market. Readers of the report can become informed about current and future trends of the global Specific Antiviral Drugs for COVID-19 market and how they will impact market growth during the forecast period.



By Company


Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group
Segment by Type
Tablet
Injection

Segment by Application


Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Specific Antiviral Drugs for COVID-19 in global and regional level.
Chapter 3Detailed analysis of Specific Antiviral Drugs for COVID-19 companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Specific Antiviral Drugs for COVID-19 revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Type: 2018 VS 2023 VS 2033
1.2.2 Tablet
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Specific Antiviral Drugs for COVID-19 Market Growth Rate by Application: 2018 VS 2023 VS 2033
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
2.2 Specific Antiviral Drugs for COVID-19 Market Size across Key Geographies Worldwide: 2018 VS 2023 VS 2033
2.3 Global Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2023)
2.4 Global Specific Antiviral Drugs for COVID-19 Market Size Forecast by Region (2024-2033)
2.5 Global Top 10 Specific Antiviral Drugs for COVID-19 Countries Ranking by Market Size
3 Specific Antiviral Drugs for COVID-19 Competitive by Company
3.1 Global Specific Antiviral Drugs for COVID-19 Revenue by Players
3.1.1 Global Specific Antiviral Drugs for COVID-19 Revenue by Players (2018-2023)
3.1.2 Global Specific Antiviral Drugs for COVID-19 Market Share by Players (2018-2023)
3.2 Global Specific Antiviral Drugs for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Specific Antiviral Drugs for COVID-19 Revenue
3.4 Global Specific Antiviral Drugs for COVID-19 Market Concentration Ratio
3.4.1 Global Specific Antiviral Drugs for COVID-19 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Specific Antiviral Drugs for COVID-19 Revenue in 2023
3.5 Global Key Players of Specific Antiviral Drugs for COVID-19 Head office and Area Served
3.6 Global Key Players of Specific Antiviral Drugs for COVID-19, Product and Application
3.7 Global Key Players of Specific Antiviral Drugs for COVID-19, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Specific Antiviral Drugs for COVID-19 Breakdown Data by Type
4.1 Global Specific Antiviral Drugs for COVID-19 Historic Revenue by Type (2018-2023)
4.2 Global Specific Antiviral Drugs for COVID-19 Forecasted Revenue by Type (2024-2033)
5 Global Specific Antiviral Drugs for COVID-19 Breakdown Data by Application
5.1 Global Specific Antiviral Drugs for COVID-19 Historic Market Size by Application (2018-2023)
5.2 Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023)
6.2 North America Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2033)
6.3 North America Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2033)
6.4 North America Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2033)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023)
7.2 Europe Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2033)
7.3 Europe Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2033)
7.4 Europe Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2033)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023)
8.2 Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2033)
8.3 Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2033)
8.4 Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Region (2018-2033)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 China Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
9 Latin America
9.1 Latin America Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023)
9.2 Latin America Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2033)
9.3 Latin America Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2033)
9.4 Latin America Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2033)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023)
10.2 Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2033)
10.3 Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2033)
10.4 Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2033)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Products and Services
11.1.4 Sanofi Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.1.5 Sanofi Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.1.6 Sanofi Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Specific Antiviral Drugs for COVID-19 Products and Services
11.2.4 Novartis Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.2.5 Novartis Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.2.6 Novartis Recent Development
11.3 Shanghai Zhongxisanwei
11.3.1 Shanghai Zhongxisanwei Company Details
11.3.2 Shanghai Zhongxisanwei Business Overview
11.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Products and Services
11.3.4 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.3.5 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.3.6 Shanghai Zhongxisanwei Recent Development
11.4 Teva
11.4.1 Teva Company Details
11.4.2 Teva Business Overview
11.4.3 Teva Specific Antiviral Drugs for COVID-19 Products and Services
11.4.4 Teva Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.4.5 Teva Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.4.6 Teva Recent Development
11.5 Zydus Cadila
11.5.1 Zydus Cadila Company Details
11.5.2 Zydus Cadila Business Overview
11.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Products and Services
11.5.4 Zydus Cadila Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.5.5 Zydus Cadila Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.5.6 Zydus Cadila Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Specific Antiviral Drugs for COVID-19 Products and Services
11.6.4 Mylan Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.6.5 Mylan Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.6.6 Mylan Recent Development
11.7 Apotex
11.7.1 Apotex Company Details
11.7.2 Apotex Business Overview
11.7.3 Apotex Specific Antiviral Drugs for COVID-19 Products and Services
11.7.4 Apotex Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.7.5 Apotex Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.7.6 Apotex Recent Development
11.8 Advanz Pharma
11.8.1 Advanz Pharma Company Details
11.8.2 Advanz Pharma Business Overview
11.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Products and Services
11.8.4 Advanz Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.8.5 Advanz Pharma Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.8.6 Advanz Pharma Recent Development
11.9 Sun Pharma
11.9.1 Sun Pharma Company Details
11.9.2 Sun Pharma Business Overview
11.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Products and Services
11.9.4 Sun Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.9.5 Sun Pharma Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.9.6 Sun Pharma Recent Development
11.10 Kyung Poong
11.10.1 Kyung Poong Company Details
11.10.2 Kyung Poong Business Overview
11.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Products and Services
11.10.4 Kyung Poong Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.10.5 Kyung Poong Specific Antiviral Drugs for COVID-19 SWOT Analysis
11.10.6 Kyung Poong Recent Development
11.11 Ipca Laboratories
11.11.1 Ipca Laboratories Company Details
11.11.2 Ipca Laboratories Business Overview
11.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Products and Services
11.11.4 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.11.5 Ipca Laboratories Recent Development
11.12 Hanlim Pharmaceutical
11.12.1 Hanlim Pharmaceutical Company Details
11.12.2 Hanlim Pharmaceutical Business Overview
11.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Products and Services
11.12.4 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.12.5 Hanlim Pharmaceutical Recent Development
11.13 Bristol Laboratories
11.13.1 Bristol Laboratories Company Details
11.13.2 Bristol Laboratories Business Overview
11.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Products and Services
11.13.4 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.13.5 Bristol Laboratories Recent Development
11.14 Bayer
11.14.1 Bayer Company Details
11.14.2 Bayer Business Overview
11.14.3 Bayer Specific Antiviral Drugs for COVID-19 Products and Services
11.14.4 Bayer Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.14.5 Bayer Recent Development
11.15 Rising Pharmaceutical
11.15.1 Rising Pharmaceutical Company Details
11.15.2 Rising Pharmaceutical Business Overview
11.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Products and Services
11.15.4 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.15.5 Rising Pharmaceutical Recent Development
11.16 Shanghai Pharma
11.16.1 Shanghai Pharma Company Details
11.16.2 Shanghai Pharma Business Overview
11.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Products and Services
11.16.4 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.16.5 Shanghai Pharma Recent Development
11.17 Sichuan Sunny Hope
11.17.1 Sichuan Sunny Hope Company Details
11.17.2 Sichuan Sunny Hope Business Overview
11.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Products and Services
11.17.4 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.17.5 Sichuan Sunny Hope Recent Development
11.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
11.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Company Details
11.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview
11.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Products and Services
11.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development
11.19 CSPC Group
11.19.1 CSPC Group Company Details
11.19.2 CSPC Group Business Overview
11.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Products and Services
11.19.4 CSPC Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.19.5 CSPC Group Recent Development
11.20 KPC Group
11.20.1 KPC Group Company Details
11.20.2 KPC Group Business Overview
11.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Products and Services
11.20.4 KPC Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.20.5 KPC Group Recent Development
11.21 Jinghua Pharmaceutical Group
11.21.1 Jinghua Pharmaceutical Group Company Details
11.21.2 Jinghua Pharmaceutical Group Business Overview
11.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products and Services
11.21.4 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.21.5 Jinghua Pharmaceutical Group Recent Development
11.22 Zhongsheng Pharma
11.22.1 Zhongsheng Pharma Company Details
11.22.2 Zhongsheng Pharma Business Overview
11.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Products and Services
11.22.4 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.22.5 Zhongsheng Pharma Recent Development
11.23 North China Pharmaceutical Group
11.23.1 North China Pharmaceutical Group Company Details
11.23.2 North China Pharmaceutical Group Business Overview
11.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products and Services
11.23.4 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.23.5 North China Pharmaceutical Group Recent Development
12 Specific Antiviral Drugs for COVID-19 Market Dynamics
12.1 Specific Antiviral Drugs for COVID-19 Industry Trends
12.2 Specific Antiviral Drugs for COVID-19 Market Drivers
12.3 Specific Antiviral Drugs for COVID-19 Market Challenges
12.4 Specific Antiviral Drugs for COVID-19 Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2023 VS 2033
Table 2. Key Players of Tablet
Table 3. Key Players of Injection
Table 4. Global Specific Antiviral Drugs for COVID-19 Market Size Growth Rate by Application (US$ Million), 2018 VS 2023 VS 2033
Table 5. Global Specific Antiviral Drugs for COVID-19 Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2023 VS 2033
Table 6. Global Specific Antiviral Drugs for COVID-19 Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Specific Antiviral Drugs for COVID-19 Revenue Forecast by Region (2024-2033) & (US$ Million)
Table 8. Global Specific Antiviral Drugs for COVID-19 Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Table 9. Global Specific Antiviral Drugs for COVID-19 Revenue by Players (2018-2023) & (US$ Million)
Table 10. Global Specific Antiviral Drugs for COVID-19 Market Share by Players (2018-2023)
Table 11. Global Top Specific Antiviral Drugs for COVID-19 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2023)
Table 12. Ranking of Global Top Specific Antiviral Drugs for COVID-19 Companies by Revenue (US$ Million) in 2023
Table 13. Global 5 Largest Players Market Share by Specific Antiviral Drugs for COVID-19 Revenue (CR5 and HHI) & (2018-2023)
Table 14. Global Key Players of Specific Antiviral Drugs for COVID-19, Headquarters and Area Served
Table 15. Global Key Players of Specific Antiviral Drugs for COVID-19, Product and Application
Table 16. Global Key Players of Specific Antiviral Drugs for COVID-19, Date of Enter into This Industry
Table 17. Mergers & Acquisitions, Expansion Plans
Table 18. Global Specific Antiviral Drugs for COVID-19 Market Size by Type (2018-2023) & (US$ Million)
Table 19. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2023)
Table 20. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 21. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2024-2033)
Table 22. Global Specific Antiviral Drugs for COVID-19 Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2023)
Table 24. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2024-2033)
Table 26. North America Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023) & (US$ Million)
Table 27. North America Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 28. North America Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 29. North America Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 30. North America Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 31. North America Specific Antiviral Drugs for COVID-19 Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 32. North America Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 33. North America Specific Antiviral Drugs for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 34. Europe Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023) & (US$ Million)
Table 35. Europe Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 36. Europe Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 37. Europe Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 38. Europe Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 39. Europe Specific Antiviral Drugs for COVID-19 Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 40. Europe Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 41. Europe Specific Antiviral Drugs for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 42. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023) & (US$ Million)
Table 43. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 44. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 45. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 46. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 47. Asia-Pacific Specific Antiviral Drugs for COVID-19 Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 48. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Region (2018-2023) & (US$ Million)
Table 49. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue by Region (2024-2033) & (US$ Million)
Table 50. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023) & (US$ Million)
Table 51. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 52. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 53. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 54. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 55. Latin America Specific Antiviral Drugs for COVID-19 Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 56. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 57. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 58. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Company (2021-2023) & (US$ Million)
Table 59. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 60. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 61. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 62. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 63. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2023 VS 2033
Table 64. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Country (2018-2023) & (US$ Million)
Table 65. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Country (2024-2033) & (US$ Million)
Table 66. Sanofi Company Details
Table 67. Sanofi Business Overview
Table 68. Sanofi Specific Antiviral Drugs for COVID-19 Product and Services
Table 69. Sanofi Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 70. Sanofi Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 71. Sanofi Recent Development
Table 72. Novartis Company Details
Table 73. Novartis Business Overview
Table 74. Novartis Specific Antiviral Drugs for COVID-19 Product and Services
Table 75. Novartis Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 76. Novartis Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 77. Novartis Recent Development
Table 78. Shanghai Zhongxisanwei Company Details
Table 79. Shanghai Zhongxisanwei Business Overview
Table 80. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Product and Services
Table 81. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 82. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 83. Shanghai Zhongxisanwei Recent Development
Table 84. Teva Company Details
Table 85. Teva Business Overview
Table 86. Teva Specific Antiviral Drugs for COVID-19 Product and Services
Table 87. Teva Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 88. Teva Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 89. Teva Recent Development
Table 90. Zydus Cadila Company Details
Table 91. Zydus Cadila Business Overview
Table 92. Zydus Cadila Specific Antiviral Drugs for COVID-19 Product and Services
Table 93. Zydus Cadila Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 94. Zydus Cadila Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 95. Zydus Cadila Recent Development
Table 96. Mylan Company Details
Table 97. Mylan Business Overview
Table 98. Mylan Specific Antiviral Drugs for COVID-19 Product and Services
Table 99. Mylan Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 100. Mylan Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 101. Mylan Recent Development
Table 102. Apotex Company Details
Table 103. Apotex Business Overview
Table 104. Apotex Specific Antiviral Drugs for COVID-19 Product and Services
Table 105. Apotex Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 106. Apotex Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 107. Apotex Recent Development
Table 108. Advanz Pharma Company Details
Table 109. Advanz Pharma Business Overview
Table 110. Advanz Pharma Specific Antiviral Drugs for COVID-19 Product and Services
Table 111. Advanz Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 112. Advanz Pharma Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 113. Advanz Pharma Recent Development
Table 114. Sun Pharma Company Details
Table 115. Sun Pharma Business Overview
Table 116. Sun Pharma Specific Antiviral Drugs for COVID-19 Product and Services
Table 117. Sun Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 118. Sun Pharma Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 119. Sun Pharma Recent Development
Table 120. Kyung Poong Company Details
Table 121. Kyung Poong Business Overview
Table 122. Kyung Poong Specific Antiviral Drugs for COVID-19 Product and Services
Table 123. Kyung Poong Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 124. Kyung Poong Specific Antiviral Drugs for COVID-19 SWOT Analysis
Table 125. Kyung Poong Recent Development
Table 126. Ipca Laboratories Company Details
Table 127. Ipca Laboratories Business Overview
Table 128. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Product and Services
Table 129. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 130. Ipca Laboratories Recent Development
Table 131. Hanlim Pharmaceutical Company Details
Table 132. Hanlim Pharmaceutical Business Overview
Table 133. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Product and Services
Table 134. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 135. Hanlim Pharmaceutical Recent Development
Table 136. Bristol Laboratories Company Details
Table 137. Bristol Laboratories Business Overview
Table 138. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Product and Services
Table 139. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 140. Bristol Laboratories Recent Development
Table 141. Bayer Company Details
Table 142. Bayer Business Overview
Table 143. Bayer Specific Antiviral Drugs for COVID-19 Product and Services
Table 144. Bayer Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 145. Bayer Recent Development
Table 146. Rising Pharmaceutical Company Details
Table 147. Rising Pharmaceutical Business Overview
Table 148. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Product and Services
Table 149. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 150. Rising Pharmaceutical Recent Development
Table 151. Shanghai Pharma Company Details
Table 152. Shanghai Pharma Business Overview
Table 153. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Product and Services
Table 154. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 155. Shanghai Pharma Recent Development
Table 156. Sichuan Sunny Hope Company Details
Table 157. Sichuan Sunny Hope Business Overview
Table 158. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Product and Services
Table 159. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 160. Sichuan Sunny Hope Recent Development
Table 161. Guangzhou Baiyunshan Guanghua Pharmaceutical Company Details
Table 162. Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview
Table 163. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Product and Services
Table 164. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 165. Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development
Table 166. CSPC Group Company Details
Table 167. CSPC Group Business Overview
Table 168. CSPC Group Specific Antiviral Drugs for COVID-19 Product and Services
Table 169. CSPC Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 170. CSPC Group Recent Development
Table 171. KPC Group Company Details
Table 172. KPC Group Business Overview
Table 173. KPC Group Specific Antiviral Drugs for COVID-19 Product and Services
Table 174. KPC Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 175. KPC Group Recent Development
Table 176. Jinghua Pharmaceutical Group Company Details
Table 177. Jinghua Pharmaceutical Group Business Overview
Table 178. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product and Services
Table 179. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 180. Jinghua Pharmaceutical Group Recent Development
Table 181. Zhongsheng Pharma Company Details
Table 182. Zhongsheng Pharma Business Overview
Table 183. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Product and Services
Table 184. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 185. Zhongsheng Pharma Recent Development
Table 186. North China Pharmaceutical Group Company Details
Table 187. North China Pharmaceutical Group Business Overview
Table 188. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Product and Services
Table 189. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023) & (US$ Million)
Table 190. North China Pharmaceutical Group Recent Development
Table 191. Specific Antiviral Drugs for COVID-19 Market Trends
Table 192. Specific Antiviral Drugs for COVID-19 Market Drivers
Table 193. Specific Antiviral Drugs for COVID-19 Market Challenges
Table 194. Specific Antiviral Drugs for COVID-19 Market Restraints
Table 195. Research Programs/Design for This Report
Table 196. Key Data Information from Secondary Sources
Table 197. Key Data Information from Primary Sources
List of Figures
Figure 1. Specific Antiviral Drugs for COVID-19 Product Picture
Figure 2. Global Specific Antiviral Drugs for COVID-19 Market Size by Type (US$ Million): 2018 VS 2023 VS 2033
Figure 3. Global Specific Antiviral Drugs for COVID-19 Market Share by Type: 2023 VS 2033
Figure 4. Tablet Features
Figure 5. Injection Features
Figure 6. Global Specific Antiviral Drugs for COVID-19 Market Size by Application (US$ Million): 2018 VS 2023 VS 2033
Figure 7. Global Specific Antiviral Drugs for COVID-19 Market Share by Application: 2023 VS 2033
Figure 8. Mild Symptom Patient
Figure 9. Critically Ill Patient
Figure 10. Specific Antiviral Drugs for COVID-19 Report Years Considered
Figure 11. Global Specific Antiviral Drugs for COVID-19 Revenue, (US$ Million), 2018 VS 2023 VS 2033
Figure 12. Global Specific Antiviral Drugs for COVID-19 Market Size 2018-2033 (US$ Million)
Figure 13. Global Specific Antiviral Drugs for COVID-19 Market Size Market Share by Region: 2023 VS 2033
Figure 14. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Region in 2018 VS 2023
Figure 15. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share Forecast by Region (2024-2033)
Figure 16. Global Top 10 Specific Antiviral Drugs for COVID-19 Countries Ranking by Market Size (US$ Million) in 2023
Figure 17. Global Specific Antiviral Drugs for COVID-19 Market Size of Top 10 Countries, 2018 VS 2023 VS 2033, (US$ Million)
Figure 18. Global Specific Antiviral Drugs for COVID-19 Market Share by Players in 2023
Figure 19. Global Top Specific Antiviral Drugs for COVID-19 Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Specific Antiviral Drugs for COVID-19 Revenue in 2023
Figure 21. North America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Company in 2023
Figure 22. North America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 23. North America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 24. North America Specific Antiviral Drugs for COVID-19 Revenue Share by Country (2018-2033)
Figure 25. United States Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 26. Canada Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 27. Europe Specific Antiviral Drugs for COVID-19 Revenue Market Share by Company in 2023
Figure 28. Europe Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 29. Europe Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 30. Europe Specific Antiviral Drugs for COVID-19 Revenue Share by Country (2018-2033)
Figure 31. Germany Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 32. France Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 33. U.K. Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 34. Italy Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 35. Russia Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 36. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue Market Share by Company in 2023
Figure 37. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 38. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 39. Asia Pacific Specific Antiviral Drugs for COVID-19 Revenue Share by Region (2018-2033)
Figure 40. China Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 41. Japan Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 42. South Korea Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 43. India Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 44. Australia Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 45. China Taiwan Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 46. Indonesia Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 47. Thailand Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 48. Malaysia Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 49. Latin America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Company in 2023
Figure 50. Latin America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 51. Latin America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 52. Latin America Specific Antiviral Drugs for COVID-19 Revenue Share by Country (2018-2033)
Figure 53. Mexico Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 54. Brazil Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 55. Argentina Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 56. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Market Share by Company in 2023
Figure 57. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 58. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 59. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Share by Country (2018-2033)
Figure 60. Turkey Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 61. Saudi Arabia Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 62. UAE Specific Antiviral Drugs for COVID-19 Revenue (2018-2033) & (US$ Million)
Figure 63. Sanofi Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 64. Novartis Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 65. Shanghai Zhongxisanwei Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 66. Teva Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 67. Zydus Cadila Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 68. Mylan Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 69. Apotex Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 70. Advanz Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 71. Sun Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 72. Kyung Poong Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 73. Ipca Laboratories Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 74. Hanlim Pharmaceutical Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 75. Bristol Laboratories Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 76. Bayer Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 77. Rising Pharmaceutical Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 78. Shanghai Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 79. Sichuan Sunny Hope Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 80. Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 81. CSPC Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 82. KPC Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 83. Jinghua Pharmaceutical Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 84. Zhongsheng Pharma Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 85. North China Pharmaceutical Group Revenue Growth Rate in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed